Surgical robotics company, Quantum Surgical, has today announced the successful completion of a first multicenter clinical study with its Epione® medical robot dedicated to minimally invasive liver cancer treatment.
The Epione® platform is designed to assist the physician in performing safer and more efficient percutaneous ablations in the liver (a minimally invasive treatment in which a needle is inserted through the skin to the lesion to burn it).
Professor Boris GUIU, Professor Thierry DE BAERE and their respective teams successfully treated 21 patients with the assistance of Epione® in this clinical trial carried out at Montpellier University Hospital (Montpellier, France) and at Gustave Roussy Cancer Center (Villejuif, France).
During these interventions, 24 liver tumors, whether they were primary (from the liver) or metastatic (from another organ) were successfully targeted and destroyed and furthermore the postoperative exams revealed no complications.
“The 21 patients treated were able to benefit from an innovative robotic guidance platform assisting in CT-guided percutaneous tumor destruction treatments. These patients were efficiently treated, pending definitive results which seem encouraging” explains Professor Boris GUIU, Interventional Radiologist, Head of the Department of Diagnostic and Interventional Radiology of Saint Eloi (Montpellier University Hospital) and Professor Thierry DE BAERE, Head of the Therapeutic Imaging Department at Gustave Roussy.
“The completion of this first clinical trial is a key milestone to Epione’s® premarket approval” announces Bertin NAHUM, President and Founder of Quantum Surgical.